Drug Trial Radar · NCT02332668
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
370
Planned (sponsor's estimate)
Start
Mar 19, 2015
Primary completion
Feb 2, 2028
Study completion Feb 2, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away. With Amendment 8, enrollment of participants with solid tumors and participants 6 months to under 12 years old with melanoma were closed. With Amendment 13, enrollment was closed for participants with relapsed refractory classical Hodgkin lymphoma (rrCHL), microsatellite instabilty-high (MSI-H) solid tumors, tumor-mutational burden-high (TMB-H) solid tumors, and participants 12 years old to \<18 years old with advanced melanoma.
Conditions
- Melanoma
- Lymphoma
- Solid Tumor
- Classical Hodgkin Lymphoma
- Microsatellite-instability-high Solid Tumor
Interventions
PembrolizumabBiological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors and Other Lymphoma Version 1.1 (RECIST 1.1) per Site Assessment (Each Disease Indication Evaluated Separately)Time frame: Up to 2 years
- ORR by RECIST 1.1 per Site Assessment for MSI-H or TMBH Solid Tumors (Each Cohort Evaluated Separately)Time frame: Up to 2 years
- ORR by International Working Group (IWG) Response Criteria (Cheson, 2007) per Blinded Independent Central Review (BICR) Assessment for rrcHL CohortTime frame: Up to approximately 2 years
- Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (Up to 21 days)
- Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to 27 months
- Number of Participants Discontinuing Study Drug Due to AEsTime frame: Up to 2 years
Locations
15 sites in 9 countries. Site status is shown where the registry gives one.
Call for Information (Investigational Site 0019)
Aurora, Colorado · Recruiting
Call for Information (Investigational Site 0024)
Chicago, Illinois · Recruiting
Call for Information (Investigational Site 0026)
Boston, Massachusetts · Recruiting
Call for Information (Investigational Site 0031)
New York, New York · Recruiting
Call for Information (Investigational Site 0070)
Fargo, North Dakota · Recruiting
Call for Information (Investigational Site 0071)
Sioux Falls, South Dakota · Recruiting
Call for Information (Investigational Site 0054)
Dallas, Texas · Recruiting
MSD Brasil
São Paulo, Brazil · Recruiting
MSD France
Paris, France · Recruiting
MSD Sharp & Dohme GmbH
München, Germany · Recruiting
MSD Italia S.r.l.
Rome, Italy · Recruiting
Merck Sharp & Dohme Lda.
Paço de Arcos, Portugal · Recruiting
MSD Korea LTD
Seoul, South Korea · Recruiting
MSD Sweden
Stockholm, Sweden · Recruiting
Merck Sharp & Dohme Ltd.
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.